Our data show that LNP-mediated delivery of the HER2-CD3-Fc mRNA resulted in the robust and sustained expression of the HER2-CD3-Fc bsAb in various types of cells, which induced a potent and highly specific T-cell-dependent antitumor effect against multiple HER2-positive tumor cells in vitro. This evidence concerns the gene ERBB2 and neoplasm.